Illumina, Inc. $ILMN Shares Purchased by Ieq Capital LLC

Key Points

• Ieq Capital LLC increased its holdings in Illumina, Inc. by 141.3%, acquiring an additional 40,291 shares during the first quarter, bringing its total to 68,798 shares valued at $5,458,000.
• Analysts have mixed opinions on Illumina's stock, with six analysts rating it as a buy, while others have set a mixed range of target prices, notably Royal Bank Of Canada raising its target to $126.00.
• Illumina reported a net margin of 29.36% in its latest quarterly earnings, with an EPS of $1.19 exceeding analysts' estimates, despite a 4.8% decline in revenue year-over-year.

Ieq Capital LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 141.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,798 shares of the life sciences company's stock after purchasing an additional 40,291 shares during the period. Ieq Capital LLC's holdings in Illumina were worth $5,458,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Illumina by 3.5% during the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after purchasing an additional 558,243 shares during the last quarter. WCM Investment Management LLC raised its position in Illumina by 1.2% in the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after purchasing an additional 49,156 shares during the period. Brown Advisory Inc. lifted its stake in shares of Illumina by 52.1% in the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after purchasing an additional 996,589 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Illumina by 26.9% during the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after purchasing an additional 349,878 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Illumina by 2.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,292,407 shares of the life sciences company's stock worth $172,704,000 after purchasing an additional 32,270 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.8%

Shares of ILMN stock traded down $0.75 on Thursday, reaching $95.32. 322,530 shares of the stock were exchanged, compared to its average volume of 2,282,178. The company has a market capitalization of $14.65 billion, a price-to-earnings ratio of 12.06, a PEG ratio of 2.25 and a beta of 1.43. The business's 50 day moving average price is $99.47 and its 200 day moving average price is $88.58. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina's revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ILMN shares. Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target on the stock. in a research note on Tuesday, August 12th. Scotiabank lowered Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a research report on Friday, July 11th. Evercore ISI upped their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Stephens set a $110.00 price objective on Illumina and gave the company an "overweight" rating in a research note on Monday, August 4th. Finally, Robert W. Baird boosted their price objective on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Illumina presently has a consensus rating of "Hold" and a consensus price target of $123.06.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.